Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Allon Therapeutics Inc NPCUF

Allon Therapeutics, Inc. is a Canada-based Company, which develops treatments for neurodegenerative diseases. The Company is engaged in pre-clinical and clinical development of proprietary neuroprotective compounds which may be applied for the potential treatment of Alzheimer's Disease, Parkinson's Disease, senile dementia, glaucoma, traumatic head injury, neuronal damage due to stroke and other conditions involving neurodegeneration. The Company's drug, davunetide, is proceeding in a pivotal Phase 2/3 clinical trial in an orphan indication, progressive supranuclear palsy (PSP), under a Special Protocol Assessment (SPA) with the Food and Drug Administration (FDA).


GREY:NPCUF - Post by User

Post by Aberta1on Jan 26, 2017 8:00am
179 Views
Post# 25756967

Globe says NAPEC rated "outperform" in new coverage

Globe says NAPEC rated "outperform" in new coverage

Globe says NAPEC rated "outperform" in new coverage

 

2017-01-26 07:47 ET - In the News

 

The Globe and Mail reports in its Thursday, Jan. 26, edition that Raymond James analyst Frederic Bastien says NAPEC currently provides an "excellent" entry point for investors. The Globe's David Leeder writes in the Eye On Equities column that Mr. Bastien began coverage on NAPEC with an "outperform" rating. Mr. Bastien set a target price for the stock of $1.40, matching the average expectation of analysts. Mr. Bastien says in a note: "There is potential for further improvements next year, as NAPEC's restructuring efforts yield additional savings and scale drives operating leverage. This, at least, is what is implicit in our sector-leading EBITDA margin target of 8.7 per cent for 2018. The stock notably trades at an EV/EBITDA [enterprise value to earnings before interest, taxes, depreciation and amortization] multiple of five times our 2017 estimates, versus average multiples of 6.2 times for the three Canadian contractors we cover and 8.2 times for a better representative group of U.S. specialty contractors. Assuming NAPEC delivers on its well-laid out strategic plan and the market rewards the company appropriately, we believe investors could be staring at a $2 stock price in two years' time."

<< Previous
Bullboard Posts
Next >>